Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies

被引:70
作者
Cross, SE
Anderson, C
Roberts, MS [1 ]
机构
[1] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[2] Univ Hosp, Dept Dermatol, Linkoping, Sweden
关键词
methylsalicylate; glycolsalicylate; triethanolamine; percutaneous;
D O I
10.1046/j.1365-2125.1998.00045.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The penetration of active ingredients from topically applied anti-inflammatory pharmaceutical products into tissues below the skin is the basis of their therapeutic efficacy. There is still controversy as to whether these agents are capable of direct penetration by diffusion through the tissues or whether redistribution in the systemic circulation is responsible for their tissue deposition below the application site. Methods The extent of direct penetration of salicylate from commercial ester and salt formulations into the dermal and subcutaneous tissue of human volunteers was determined using the technique of cutaneous microdialysis. We also examined differences in the extent of hydrolysis of the methylester of salicylate applied topically in human volunteers and in vitro skin diffusion cells using full-thickness skin and epidermal membranes. Results The present study showed that whilst significant levels of salicylate could be detected in the dermis and subcutaneous tissue of volunteers treated with the methylsalicylate formulation, negligible levels of salicylate were seen following application of the triethanolamine salicylate formulation. The tissue levels of salicylate from the methylsalicylate formulation were approx. 30-fold higher than the plasma concentrations. Conclusion The absorption and tissue concentration profiles for the commercial methylsalicylate formulation are indicative of direct tissue penetration and not solely redistribution by the systemic blood supply.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 24 条
[11]   MICRODIALYSIS IN CUTANEOUS PHARMACOLOGY - KINETIC-ANALYSIS OF TRANSDERMALLY DELIVERED NICOTINE [J].
HEGEMANN, L ;
FORSTINGER, C ;
PARTSCH, B ;
LAGLER, I ;
KROTZ, S ;
WOLFF, K .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (05) :839-843
[12]   CUTANEOUS METABOLISM OF XENOBIOTICS [J].
KAO, J ;
CARVER, MP .
DRUG METABOLISM REVIEWS, 1990, 22 (04) :363-410
[13]   Percutaneous absorption of salicylates from some commercially available topical products containing methyl salicylate or salicylate salts in rats [J].
Megwa, SA ;
Benson, HAE ;
Roberts, MS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (11) :891-896
[14]   Serum concentrations of salicylic acid following topically applied salicylate derivatives [J].
Morra, P ;
Bartle, WR ;
Walker, SE ;
Lee, SN ;
Bowles, SK ;
Reeves, RA .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (09) :935-940
[15]   IN-VIVO CHARACTERIZATION OF TRANSDERMAL DRUG TRANSPORT BY MICRODIALYSIS [J].
MULLER, M ;
SCHMID, R ;
WAGNER, O ;
VONOSTEN, B ;
SHAYGANFAR, H ;
EICHLER, HG .
JOURNAL OF CONTROLLED RELEASE, 1995, 37 (1-2) :49-57
[16]  
Neubert R, 1990, Dermatol Monatsschr, V176, P711
[17]   KINETICS OF TRANSDERMAL PENETRATION OF AN ORGANIC ION-PAIR - PHYSOSTIGMINE SALICYLATE [J].
PARDO, A ;
SHIRI, Y ;
COHEN, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (10) :990-995
[18]   DICLOFENAC CONCENTRATIONS IN SYNOVIAL-FLUID AND PLASMA AFTER CUTANEOUS APPLICATION IN INFLAMMATORY AND DEGENERATIVE JOINT DISEASE [J].
RADERMACHER, J ;
JENTSCH, D ;
SCHOLL, MA ;
LUSTINETZ, T ;
FROLICH, JC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) :537-541
[19]   TOPICAL BIOAVAILABILITY OF METHYL SALICYLATE [J].
ROBERTS, MS ;
FAVRETTO, WA ;
MEYER, A ;
RECKMANN, M ;
WONGSEELASHOTE, T .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1982, 12 (03) :303-305
[20]  
Schaefer H, 1996, SKIN BARRIER PRINCIP, P213